Naproxen Hermes (Naproxen)

Naproxen blocks the activity of cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for the production of prostaglandins. By lowering prostaglandin levels, it diminishes the sensitisation of pain receptors and curtails the inflammatory cascade, providing analgesic, anti‑inflammatory and antipyretic effects.

The appropriate dose of Naproxen Hermes is determined by the prescribing healthcare professional based on the patient’s condition, severity of symptoms, age, renal function and other clinical factors. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety of naproxen during pregnancy and lactation has not been fully established. It is generally avoided in the third trimester because of potential fetal cardiovascular effects, and caution is advised while breastfeeding. Physicians should weigh the benefits against possible risks before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Naproxen offers a longer half‑life than ibuprofen, allowing twice‑daily dosing for many patients, which can improve adherence. Its analgesic and anti‑inflammatory potency is comparable to other non‑selective NSAIDs, but individual tolerability, gastrointestinal risk and cardiovascular profile may differ, influencing drug choice.

Naproxen Hermes should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The medication is taken orally, usually with a full glass of water. It can be taken with or without food, although taking it with meals may reduce gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include gastrointestinal bleeding or ulceration, renal impairment, cardiovascular events such as heart attack or stroke, severe skin reactions (e.g., Stevens‑Johnson syndrome), and anaphylaxis. Patients should be monitored for signs of these complications and seek immediate medical attention if they occur.

Individuals with a known hypersensitivity to naproxen or any other NSAID, those with active gastrointestinal ulceration, severe renal or hepatic impairment, uncontrolled hypertension, or a history of cardiovascular thrombotic events should avoid using Naproxen Hermes unless specifically directed by a physician.